Nintena 100mg Capsule

Most side effects of Nintena 100mg Capsule do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.

Common side effects include:

• Abdominal pain
  
• Diarrhea
  
• Nausea
  
• Vomiting
  
• Abnormal liver function tests
  
• Loss of appetite
  
• Headache
  
• Weight loss
  
• High blood pressure
  

Doctor determines the exact dose and duration with Nintena 100mg Capsule as per the overall health condition of the patient. The typical recommended dose of the capsule is twice daily.

This capsule should be taken with food, but at the fix time every day to get effective results. Don't miss a dose or overdose on the medicine. Swallow it as a whole with a glass of water and do not crush, chew, or open it.

Nintena 100mg Capsule is an anticancer medicine that contains nintedanib. This medicine works by inhibiting the pathways responsible for fibrosis and reducing the scarring & swelling in the lungs results in better breath. It also blocks the action of abnormal protein to stop or slow the spread of cancer cells.

• Reck, M., & Mellemgaard, A. (2015). Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib. Biologics: Targets and Therapy, 47-56.
  
• McCormack, P. L. (2015). Nintedanib: first global approval. Drugs, 75(1), 129-139.
  
• Rashdan, S., & Hanna, N. (2014). Nintedanib for the treatment of non-small-cell lung cancer. Expert opinion on pharmacotherapy, 15(5), 729-739.
  
• Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015). Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. European Respiratory Journal, 45(5), 1434-1445.
  
• Varone, F., Sgalla, G., Iovene, B., Bruni, T., & Richeldi, L. (2018). Nintedanib for the treatment of idiopathic pulmonary fibrosis. Expert opinion on pharmacotherapy, 19(2), 167-175.
  
• Caglevic, C., Grassi, M., Raez, L., Listi, A., Giallombardo, M., Bustamante, E., ... & Rolfo, C. (2015). Nintedanib in non-small cell lung cancer: from preclinical to approval. Therapeutic advances in respiratory disease, 9(4), 164-172.​